- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
A new executive briefing has for the first time compiled a comprehensive status report of all nano-based drugs and medical devices, providing a remarkable look at the market's quickening pulse.
A new executive briefing has for the first time compiled a comprehensive status report of all nano-based drugs and medical devices, providing a remarkable look at the market's quickening pulse. According to data compiled in the just-released NanoBiotech News 2005 Nanomedicine, Device & Diagnostic Report, 61 nanotech-based drugs and delivery systems and 91 devices or diagnostic tests have entered preclinical, clinical, or commercial development.
No longer a "nascent field," nanobiotechnology is on the cusp of launching nano-based health products that will change the face of medicine.
NanoBiotech News 2005 Nanomedicine, Device & Diagnostic Report, produced by the publishers of NanoBiotech News, includes the associated company or academic research center name, product name, type, indication and status for each of the 152 entries. Additionally, key experts provide in-depth analysis of the state of the industry and the products currently under development.
Analysts, investors, and researchers are all looking for companies with proven technology and solid progress in clinical trials. In fact, last year marked the emergence of two nanotech stock indices -- by New York-based investment firms Punk, Ziegel & Co. and Merrill Lynch (NYSE:MER).
New York-based Lux Research, Inc., expects sales of products that incorporate emerging nanotechnology to rise from less than 0.1% of global manufacturing output today to 15% in 2014, for a total of $2.6 trillion annually -- a value that approaches the size of the information technology and telecom industries combined and is 10 times larger than biotechnology revenues.
"Despite the promise of nanotechnology, experts tell us that the big pharmaceutical companies are 'flat-footed' in their nanotech initiatives, while medical device firms are more advanced in their race to develop nanotechnologies, with major players such as Baxter International Inc., Medtronic Inc., and Guidant Corporation all pursuing nanobiotech R&D," says Lynn Yoffee, associate publisher of NanoBiotech News, which produced the 2005 Nanomedicine, Device & Diagnostic Report.
"This report is unique because it's the only existing compilation of all medical products currently under development that incorporate nanotechnology," says Yoffee. "The 2005 Nanomedicine, Device & Diagnostic Report provides the hard data needed to spot important trends and seize opportunities for collaborations and competitive developments in 2005."
Industry observers and participants alike can stay on top of the field by reading NanoBiotech News every week. Every major nanomedicine development -- from both business and scientific perspectives -- is covered in this global nanobiotechnology intelligence source. To order a copy of the report, available for only $199, or to get a complimentary trial subscription to the newsletter, visit www.nanobiotechnews.com or call (404) 607-9500 or (800) 597-6300.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanoparticles that speed blood clotting may someday save lives August 23rd, 2016
Curbing the life-long effects of traumatic brain injury August 19th, 2016
New flexible material can make any window 'smart' August 23rd, 2016
University of Puerto Rico and NASA back in the news – XEI reports August 23rd, 2016